12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Company News  |  Deals

Alfa Wassermann, Theravance deal

Theravance and Alfa Wassermann partnered to develop and commercialize Theravance's velusetrag ( TD-5108) to treat gastroparesis. The partners will conduct a two-part Phase II program funded by Alfa Wassermann. Following the program,...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >